Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Professor Hill develops vaccines against malaria based on inducing cellular immune responses (T lymphocytes) instead of the more commonly used stimulation of antibodies. Prophylactic vaccines developed in Oxford are now showing great promise in clinical trials.

Q: Hello Adrian. Why is it important to research vaccines in a University rather than in a company?

AH: Well these days developing a vaccine takes a long time, typically 15 years from the idea to actually licensing the vaccine. We don't do all of that process in the University but it's really important that the early stage of vaccine research and early clinical trials are done in a setting where we can test out lots of new ideas and find the best way to vaccinate against some of these very difficult diseases. So we would typically take the vaccine from the idea to the bench to pre-clinical and then phase I and phase II clinical trials, and it's only at that stage that one of the large vaccine companies would be interested in licensing that vaccine and developing it and taking it forward for market supply.

Q: How much progress has been made producing a vaccine for malaria?

AH: Malaria's a good example of something that's very difficult to make a vaccine for and where lots of different vaccine concepts have to be tested. That's where research and academia comes in and we can try a whole variety of different vaccine approaches to try and find out what would be best, and of course it is difficult because we have no vaccines that work against any parasitic disease of humans, but malaria is showing the most signs of progress in that we have vaccines that are now protecting a significant number of people in clinical trials, not enough, but we are rapidly improving those vaccines so in phase II trials we can see some efficacy in over half the people with two completely different types of vaccine today.

Q: Is research on malaria adequately funded considering the number of people affected compared to degenerative illnesses of the rich world?

AH: For years people have debated the big problem of how you incentivize, particularly companies, to invest in Malaria vaccine design and development. We are talking about a huge amount of money, probably close to a billion pounds, from the idea to market supply of the vaccine. And that's a big risk for a company because we know it's very difficult and we know it's going to take a long time, and crucially we know that at the end of the day the people who need that vaccine most are not able to pay even a modest price for it. So we need a different mechanism and lots of thought has gone into this, but essentially it means that governments and charities have to fund most of that vaccine development process, and it's only when the vaccine is clearly working and going to work in the real world that private companies will invest in manufacturing that vaccine and supplying it. So in a way the difficult bit has to be done before it gets taken up by a company.

Q: How is your approach to this research different to other researchers?

AH: So what we're doing in our vaccine programmes is something fundamentally different to nearly all other vaccines. We're trying to make vaccines work by inducing cellular immunity not inducing antibodies and nearly every vaccine you can buy today works by inducing antibodies. So why are we doing something different? Well, we know for Malaria that by inducing cells that can kill the parasite inside infected human liver cells, possibly blood cells, we can get better protection than through the traditional way of inducing antibodies. So those vaccines are now showing promise and we believe that's the best way of vaccinating against malaria.

Q: So happens after these trials have been completed in Oxford?

AH: With vaccines for malaria of course the people we really want to vaccinate eventually are those African children; we know about a million children a year die from malaria. So already we've taken some of these vaccines into clinical trials in both West Africa and East Africa, that's at Kilifi in Kenya. There we've seen very promising results: good safety, good immune responses and we're testing those vaccines now to see if they are effective at protecting children in Kilifi against malaria.

Q: Could your approach be used to develop vaccines against other illnesses?

AH: What we're doing in malaria is also being developed for a whole variety of other infections- hepatitis C, (which is also a liver infection) tuberculosis, HIV and even cancer has this same major challenge of getting cellular immunity to work with vaccination. People are trying all sorts of ideas but the approach that we're using in malaria does seem to be one of the most promising of those out there.

Q: Finally Adrian, how does your research fit into Translational Medicine within the department?

AH: So we think that vaccinology is a great example of Translational Medicine. You can't do vaccinology without trying to translate your findings into real products either for veterinary medicine or for humans. So what we're doing is taking vaccines that are initially designed in the University and finding the best ones to take into clinical trials, and it's only when you're really in the clinic testing this on people that you get the answers about whether a vaccine is going to be useful or not. So this is a quintessential translational activity.

Adrian Hill

Innovative Vaccines against Major Global Diseases

Professor Adrian Hill has been studying the immune system and malaria susceptibility in African children for years. We asked him about his latest findings in the development of vaccines against malaria.

More podcasts related to Malaria

Bob Taylor: Primaquine for vivax and falciparum malaria

Primaquine can be used both to treat vivax malaria and to prevent the transmission of falciparum malaria from human to mosquito. A shorter and age-based primaquine regimen would reduce the burden of vivax malaria. It would also allow primaquine to be used more widely to block the transmission of falciparum malaria.

Lisa White: Mathematical modelling for tropical diseases

Mathematical modelling, particularly when combined with economical modelling, allows researchers and policy makers to determine the most effective interventions to fight infectious diseases such as malaria. We can use those models to explore ‘what ifs’ scenarios, at country or province level, save more lives and limit costs.

Ric Price: Curing Plasmodium vivax malaria

Vivax malaria used to be considered benign but is now recognised as an important cause of morbidity and mortality. Resistance to chloroquine (given to treat the parasite blood stage) is growing and ACT (artemisinin-based combination therapy) is becoming common treatment for vivax malaria. New drugs and better public health strategies can help elimination targets, anticipated for 2030.

Olivo Miotto: Genomics and global health

Genomics is the study of the complete DNA sequence, for example of a particular parasite, allowing us to analyse its evolution and the impact of human interventions. Alongside clinical date, we use genomics to identify mutations that are markers for drug resistance. Mapping out drug resistance then helps inform elimination programmes.

Frank Smithuis: Fighting malaria in Myanmar

Although malaria is decreasing in Myanmar, resistance to anti-malarials is on the rise in the region and the focus is now to treat people early, particularly in remote communities. MOCRU has set up a network of community health workers, trained and supplied with diagnostics, bednets and treatments, to help improve access to healthcare as well as produce the evidence to encourage policy changes.

Andrea Ruecker: Blocking malaria transmission

In the falciparum malaria parasite cycle, the gametocyte stages are responsible for the transmission from person to mosquito, then to other persons. A better understanding of how gametocytes respond to malaria treatments would help us block transmission and ultimately eliminate malaria.

Rob van der Pluijm: Tracking antimalarial resistance and treatment of malaria using Triple ACTs

Anti-malaria drug resistance is spreading throughout Southeast Asia and we need to find new treatments. Our researchers at MORU use a combination of artemisinin and two partner drugs instead of one. If confirmed safe and tolerable, triple artemisinin combination therapies might be a good option to treat multi-drug resistant malaria, as well as slow down the emergence and spread of anti-malarial resistance.

James Watson: Primaquine and vivax malaria

Primaquine is a drug used to eliminate vivax malaria from the liver and prevent relapses. However, it causes anaemia in patients with G6PD deficiency. A new, slightly longer regimen with increasing doses of primaquine could allow to safely treat all patients with vivax malaria.

Xin Hui Chan: Using big data to eliminate malaria

Malaria is the most important parasitic infection to still affect humans, and a safe use of antimalarial drugs is paramount. The current explosion of clinical data is causing a jungle of data; making sense of all this data will greatly help us in our fight to eliminate malaria.

Bob Snow: Malaria control in Africa

Quality data is vital to design better malaria control programmes. This project helps various African countries gather epidemiological evidence to better control malaria. Professor Bob Snow showed how sub-regional, evidence-based platforms can effectively change malaria treatment policies.

Translational Medicine

From Bench to Bedside

Ultimately, medical research must translate into improved treatments for patients. At the Nuffield Department of Medicine, our researchers collaborate to develop better health care, improved quality of life, and enhanced preventative measures for all patients. Our findings in the laboratory are translated into changes in clinical practice, from bench to bedside.